Skip to main content
MDGL
NASDAQ Life Sciences

Madrigal Posts First Profitable Quarter as Rezdiffra Sales Hit $431.3M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$477
Mkt Cap
$9.961B
52W Low
$399
52W High
$615
52W Position info
20% above low
Off High info
22% below high
Rel. Volume info
1.8× avg
Market data snapshot near publication time

MDGL sits 20% above its 52-week low of $399 on elevated volume (1.8× avg).

Summary

Madrigal reported its first profitable quarter — $55.4 million of net income on $431.3 million of Rezdiffra sales, up 50% — and crossed $1.1 billion in year-to-date sales. It also announced a new Phase 3 cirrhosis trial, with the key MAESTRO-NASH OUTCOMES data expected late 2027.


Key Events · Earnings and Guidance · MDGL

  • First Profitable Quarter

    Q3 2026 net income of $55.4 million, or $1.83 per diluted share, versus a net loss of $114.2 million ($4.01 per share) in the prior-year period.

  • Rezdiffra Sales Up 50%

    Q3 net sales of $431.3 million versus $287.3 million a year ago; year-to-date net sales of $1.1 billion make it a blockbuster.

  • Patient Count Nearly Doubles

    More than 55,850 patients on Rezdiffra as of Sept. 30, 2026, nearly double the 3Q25 level; U.S. F2-F3 addressable market on track to grow more than 30% by year-end 2026.

  • New Phase 3 Cirrhosis Trial

    MAESTRO-CSPH will enroll more than 2,000 F4c patients, with initiation expected in the first half of 2027 subject to regulatory discussions; MAESTRO-NASH OUTCOMES data expected late 2027.


Analysis · MDGL · Life Sciences

Madrigal crossed from losses to profit: Q3 net income of $55.4 million ($1.83 diluted per share) against a $114.2 million loss a year ago, on Rezdiffra net sales of $431.3 million, up 50%. Year-to-date sales of $1.1 billion make Rezdiffra a blockbuster less than three years after launch, and 55,850 patients on therapy show demand still compounding. The company also laid out its next leg: a second Phase 3 outcomes trial (MAESTRO-CSPH) in compensated cirrhosis, with the existing MAESTRO-NASH OUTCOMES readout expected late 2027. With $961.8 million in cash and the P&L now self-funding, the dilution risk that hung over the story is materially reduced.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MDGL was trading at $477.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10B. The 52-week trading range was $399.00 to $615.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MDGL - Latest Insights

MDGL
Nov 06, 2026, 5:30 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $399.93
Real-time Price: $421.99 info
Change: +$22.06 (+6%) info
Market Cap: $9.803B info
MDGL
Nov 05, 2026, 10:35 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $408.99
Real-time Price: $421.99 info
Change: +$13.00 (+3%) info
Market Cap: $9.803B info
MDGL
Nov 03, 2026, 9:10 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $428.01
Real-time Price: $421.99 info
Change: -$6.02 (-1%) info
Market Cap: $9.803B info
MDGL
Nov 03, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $431.16
Real-time Price: $421.99 info
Change: -$9.16 (-2%) info
Market Cap: $9.803B info
MDGL
Aug 03, 2026, 7:33 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $475.00
Real-time Price: $421.99 info
Change: -$53.01 (-11%) info
Market Cap: $9.803B info